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Abstract
BACKGROUND: Despite the importance of medication adherence in heart failure, clinically relevant
cutpoints for distinguishing the level of adherence associated with outcomes are unknown.
OBJECTIVE: The purpose of this study is to determine the cutpoint above which there is a positive
relationship between level of medication adherence and event-free survival.
METHODS: This was a longitudinal study of 135 patients with heart failure. Medication adherence was
measured using a valid and objective measure, the Medication Event Monitoring System. Two indicators of
adherence were assessed by the Medication Event Monitoring System (AARDEX, Union City, CA): (1) dose
count, percentage of prescribed doses taken, and (2) dose days, percentage of days the correct number of
doses was taken. Patients were followed up to 3.5 years to collect data on outcomes. A series of Kaplan-Meier
plots with log-rank tests, Cox survival analyses, and receiver operating characteristic curves were assessed
comparing event-free survival in patients divided at one-point incremental cutpoints.
RESULTS: Event-free survival was significantly better when the prescribed number of doses taken (dose
count) or the correct dose (dose day) was > or =88%. This level was confirmed in a Cox regression model
controlling for age, gender, ejection fraction, New York Heart Association, comorbidity, angiotensin-
converting enzyme inhibitor use, and beta-blocker use. Receiver operating characteristic curves showed that
adherence rates above 88% produced the optimal combination of sensitivity and specificity with respect to
predicting better event-free survival. With 88% as the adherence cutpoint, the hazard ratio for time to first
event for the nonadherent group was 2.2 by dose count (P = .021) and 3.2 by dose day (P = .002).
CONCLUSION: The results of this study provide clinicians and researchers with an evidence-based
recommendation about the level of adherence needed to achieve optimal clinical outcomes.
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Abstract
BACKGROUND—Despite the importance of medication adherence in heart failure (HF), clinically
relevant cutpoints for distinguishing the level of adherence associated with outcomes are unknown.
OBJECTIVE—To determine the cutpoint above which there is a positive relationship between level
of medication adherence and event-free survival.
METHODS—This was a longitudinal study of 135 patients with HF. Medication adherence was
measured using a valid and objective measure, the Medication Event Monitoring System (MEMS).
Two indicators of adherence were assessed by the MEMS: 1) dose-count, percentage of prescribed
doses taken and 2) dose-days, percentage of days correct number of doses taken. Patients were
followed up to 3.5 years to collect data on outcomes. A series of Kaplan-Meier plots with log-rank
tests, Cox-survival analyses, and receiver operating characteristic (ROC) curves were assessed
comparing event-free survival in patients divided at one point incremental cutpoints.
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RESULTS—Event-free survival was significantly better when the prescribed number of doses taken
(dose-count) or the correct dose (dose-day) was ≥ 88%. This level was confirmed in a Cox regression
model controlling for age, gender, ejection fraction, NYHA, comorbidity, angiotensin-converting
enzyme inhibitor use, and beta-blocker use. ROC curves showed that adherence rates above 88%
produced the optimal combination of sensitivity and specificity with respect to predicting better
event-free survival. With 88% as the adherence cutpoint, the hazard ratio for time to first event for
the nonadherent group was 2.2 by dose-count (p=.021) and 3.2 by dose-day (p=.002).
CONCLUSION—The results of this study provide clinicians and researchers with an evidence-
based recommendation about the level of adherence needed to achieve optimal clinical outcomes.
Keywords
medication adherence; heart failure; outcomes; MEMS
Introduction
Heart failure (HF) is a serious and costly cardiovascular disorder, but its natural history can be
modified by appropriate, sustained drug therapy.1 Lifelong adherence to prescribed
medications is an important determinant of optimal health outcomes. Poor adherence to
prescribed medication therapy increases the risk of mortality and morbidity2 and leads to high
health costs2, 3 and poor quality of life4 in patients with HF. A significant portion of the
healthcare advice and prescriptions dispensed at HF medical encounters was not fully
implemented due to nonadherence. The annual health care costs related to nonadherence are
estimated to be as high as $300 billion per year.5
Despite the importance of adherence, the level of medication adherence that distinguishes
clinically significant adherence vs. nonadherence is unknown.6 Although 100% medication
adherence is the desired goal, it may be unrealistic to expect patients to achieve perfect
medication adherence and there is no evidence in HF suggesting that 100% adherence is needed
to achieve optimal outcomes. In prior investigations, adherence has been defined arbitrarily as
taking between 70% and 100% of a medication as prescribed.7, 8 The reason for choosing
these cutpoints is unclear and not based on empirical data.9-13 Further, levels of medication
adherence may not be clinically relevant as they are not based on evidence that links frequency
and dosing with clinical outcomes.14 An unambiguous cutpoint is needed to help researchers
analyze data and to provide an objective adherence level for patients and clinicians.
Accordingly, the purpose of this study was to determine the level of medication adherence
associated with better health outcomes, specifically, time to the composite endpoint of
emergency department (ED) visits for HF exacerbation, cardiac rehospitalizations and all-
cause mortality.
Methods
Study Design
In this prospective study, we used the composite endpoint of time to first event (i.e., ED visit
for HF exacerbation, cardiac rehospitalization, or all-cause mortality) as a criterion to
determine the level of medication adherence required to achieve the longest time to event after
controlling for demographic and clinical variables (i.e., age, gender, medication regimen,
comorbidity, New York Heart Association [NYHA] functional class and left ventricular
ejection fraction [LVEF]).
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Samples and Setting
Detailed eligibility criteria and recruitment methods have been published previously.15
Briefly, patients were recruited from outpatient cardiology clinics in Central Kentucky. Patients
with a confirmed diagnosis of chronic HF and stable doses of HF medications were enrolled.
Patients were excluded if they had obvious cognitive impairment (i.e., not able to give informed
consent or participate in an interview) or a co-existing terminal illness such as cancer.
Measurement of Variables
Patients’ demographic and clinical data were collected by patient interview or medical record
review and medication adherence monitoring with the MEMS was started. Data on ED visits,
hospitalizations and survival were assessed monthly by phone and at the end of the study by
examining the hospital administrative database.
Medication Adherence—Medication adherence was measured continuously for 3 months
using an unobtrusive microelectronic monitoring device in the caps of a medication vial
(AARDEX®). The Medication Event Monitoring System (MEMS) is an objective measure
considered the gold-standard for the measurement of medication adherence.16, 17 An
electronic chip in the medication cap records each date and time the cap is removed from the
medication bottle. Patients were given a medication diary to record unscheduled cap openings,
such as those to refill the bottle, so that unscheduled events could be removed from analysis.
In this study, MEMS data were collected from one HF medication for each patient. Prior
research has demonstrated that monitoring one medication provides a valid indicator of all
medication-taking behavior.16, 17 The medication chosen to be monitored was based on the
following criteria. If the patient was taking a medication twice a day, this medication was
chosen for monitoring using the MEMS. If all medications were taken twice or only once per
day, then the beta-adrenergic blocking agent was chosen unless the patient was not prescribed
one. In those cases, the angiotension-converting-enzyme (ACE) inhibitor or angiotensin
receptor blocker was used. If no beta-blocker or ACE inhibitor was prescribed, digoxin or a
diuretic was used in the MEMS device.
Two indicators of medication adherence from the MEMS were used in analysis: 1) dose-count,
defined as the percentage of prescribed number of doses taken during the 3-month monitoring
period; and 2) dose-day, defined as the percentage of days the correct number of doses taken.
15 These two indicators were chosen because they were the best predictors of event-free
survival in our prior study.15 Groups (above and below a given percentage of adherence) were
created based on the medication adherence rate measured by the MEMS device.
Time to First Event—The dependent variable was the time to the first event. Events
considered were ED visits for symptoms of decompensated HF, cardiac rehospitalizations and
mortality. Patients were asked to keep a diary of events. In addition, data were determined by
a combination of medical record review, review of hospital administrative records, and patient
and family interview. Dates and reasons for events were noted after the medical record was
carefully reviewed to confirm the visit date and reason. Patients/families were interviewed to
obtain self-reports to augment automated data because the patient many have been admitted
to EDs or hospitals outside of the system. If the admission was outside the system, a patient
release was obtained and the medical record of the visit was reviewed. In all cases, conflicting
data between patient report and administrative records were resolved with review of the
medical record and interview of the patient and family.
Additional methods were used to track mortality. At enrollment, patients were asked for contact
information on a relative or close friend to be used if they could not be contacted. If unable to
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reach patients by telephone, we contacted healthcare providers and checked automated hospital
records to determine if the patient had died. If evidence was not found, we contacted the friend
or relative. If neither the patient nor their contacts could be located during follow-up or if
additional information was needed, the county death records were searched. Although death
certificates were usually a valid source of data about the date of death, they were less valid for
determining cause of death and supplemental data were always sought to establish whether the
death was cardiac or non-cardiac.
In this study, NYHA functional class, age, gender, LVEF, medication regimen and comorbidity
were collected as covariates. NYHA was determined by standardized patient interview.18
Patients’ age, gender, LVEF and medication regimen (i.e., ACE inhibitor [yes/no], β blocker
[yes/no], diuretics [yes/no], digoxin [yes/no], aldosterone antagonist [yes/no]) were collected
from the medical record, and patient interview.
Comorbidity was measured using the interview format of the Charlson Index.19, 20 At
enrollment, patients were queried about preexisting diseases (e.g., ulcer disease, diabetes).
Scores can range from 0 to 34 but because each patient had HF, they had a score of at least 1.
Validity was supported in prior research in which comorbidity category predicted mortality,
complications, health care resource use, length of hospital stay, and discharge disposition.19,
21
Protocol
Permission for the conduct of the study was obtained from the University of Kentucky (UK)
Institutional Review Board (IRB). Patients were referred to this project by nurse practitioners
in the HF clinic. Patient eligibility was confirmed by a trained research associate. The research
associate then explained study requirements to eligible patients and obtained informed, written
consent.
At baseline, patients’ sociodemographic and clinical characteristics were collected by
interview and medical record review. After interview, detailed written and verbal instructions
on use of the MEMS bottle were given to patients. Patients were informed about the purpose
of the MEMS and instructed to take the specified medicine from MEMS bottle for the next
three months and close the lid after each use. They were trained to use their medication diary
to record unscheduled cap openings. If patients opened the bottle for any reason not related to
taking medication, the time and date were recorded in the diary, so that event could be excluded,
if appropriate, when data were downloaded. Patients who used a pill box were asked to keep
the MEMS bottle beside their pill box and take that medicine from the MEMS bottle.
After three months of continuous use of the MEMS bottle, patients returned the bottle. The
data from the MEMS cap were downloaded using a manufacturer-supplied communicator and
software installed on a personal computer. Unscheduled cap openings were excluded from
analysis based on the medication diary recorded by patients. The MEMS data were then printed
and entered into a data base for further analyses.
Data Management and Analysis
All data analyses were done using SPSS, version 15.0; a significance level of .05 was used
throughout. The log-rank test was used to compare the time to event-free survival between
groups formed by dividing the sample at varying levels of adherence. Because no standard
cutpoint exists, patients were divided into groups (above and below a given percentage of
adherence) based on their medication adherence rate measured by the MEMS using one point
incremental cutpoints. Kaplan-Meier plots were used to graphically depict group differences
in event-free survival. Cox proportional hazards regression modeling was used to assess the
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time to the composite endpoint, while controlling for the following potential covariates: age,
gender, baseline NYHA, LVEF, comorbidity, ACE inhibitor use (yes/no), and any baseline
variables upon which the groups differed. Baseline difference between groups were examined
using either two-sample t-test (for continuous variables), Mann-Whitney U tests (for ordinal
variables), or chi-square tests (for nominal variables). Receiver operating characteristic (ROC)
curves were used to summarize the relationship between level of medication adherence and
the prediction of negative clinical outcomes, as a function of differing levels of adherence.
Results
Patient Characteristics
We recruited 147 of the 301 eligible HF patients approached for the study; 152 patients refused
to participate due to long travel distance, time concerns (e.g., have to take care of other family
members), no interest in participating in research, or lack of energy. In this study, we only
included data from the 135 for whom we have full data from the MEMS. MEMS data were
missing in 12 patients because of malfunction of the MEMS cap (n = 2), loss of the MEMS
cap or patient death (n = 6), or problems with the software interface (n = 4). Sample
characteristics are presented in Table 1.
Survival Analyses
Kaplan-Meier plots with log-rank tests were used to compare patients’ time to first occurrence
of the composite endpoint between groups created by various medication adherence cutpoints.
Using this method, we determined that 88% was the first cutpoint at which patients’ times to
first event were significantly different. That is, when patients were divided into two groups
that consisted of those taking ≥ 88% of the prescribed number of doses in the time period
examined (dose-count) and those taking less than 88%, adherence level predicted the composite
endpoint (Figure 1). The 88% cutpoint was also predictive of the composite endpoint using the
dose-day indicator (percentage of days the patient took the correct dose (Figure 1).
When the 88% cutpoint was identified we compared patient characteristics by groups formed
by this cutpoint (Table 1). Groups did not differ on sociodemographic characteristics; however,
adherent patients had a lower comorbidity index. Using this cutpoint, 44% of patients were
considered to be nonadherent, while the remaining 56% had adequate adherence.
The result from the Kaplan-Meier analysis was confirmed in Cox regression modeling (Table
2) after adjusting for potential confounding factors. The composite endpoint was consistently
predicted by medication adherence after controlling for sociodemographic and clinical factors
regardless of whether the dose-day or dose-count indicator was used. The hazard ratio for time
to the composite endpoint for patients with inadequate adherence was 2.2 (by dose-count) to
3.2 (by dose-day; p = .021 and .002, respectively). In addition to medication adherence for
both dose-count and dose-day models, being on a beta-blocker was an independent predictor
of the composite endpoint (p = .04 and .03, respectively).
Receiver Operating Characteristic Curves
From ROC curves, we confirmed that time to the composite endpoint between those who
adhered and did not adhere was different when a medication adherence cutoff rate = 88% was
used to dichotomize patients (p < .05). An 88% adherence rate resulted in an optimal
combination of sensitivity (.770 and .610, respectively) and specificity (.0.486 and 0.686,
respectively) in the prediction of the composite endpoint.
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Discussion
This was the first study to use patients’ composite endpoint of time to ED visit for HF
exacerbation, cardiac hospitalization and mortality as a criterion to determine the level of
medication adherence required to achieve the best clinical outcomes in patients with HF. To
date, levels of medication adherence have been defined based on expert opinion and varied
widely. Our study demonstrated that a medication adherence rate of 88% is positively
associated with a composite endpoint of time to ED visit, hospitalization and mortality
outcomes and provides a clinically relevant cutpoint for clinicians. Over a 30-day period, a
dose-count of 88% means that patients need to take at least 53 of 60 doses of a drug prescribed
twice a day. A dose-day of 88% means that patients must take the correct number of doses for
at least 26 days within a 30-day cycle. These results demonstrate that a high level of adherence
is necessary to achieve a longer event-free survival period.
There are two ways medication adherence has been reported in the adherence research: 1) data
used as a continuous variable, and 2) data used as a dichotomous variable. When investigators
used medication adherence as continuous data, they commonly found a significant relationship
between medication adherence and outcomes, even though measures of medication adherence
differed (i.e., self-report,22-24 pharmacy refill,25-27 pill count28 and the MEMS15, 29) and
patient populations differed (i.e., patients with HF,15, 22, 29, myocardial infarction,23
diabetes,24, 25 or coronary heart disease26, 28).
However, the most common method of using adherence data in the literature has been to choose
a cutpoint to dichotomize patients as adherent or nonadherent. Several investigators have
grouped patients by arbitrarily chosen cutpoints, and examined the relationship of medication
adherence with ED visits, rehospitalization and mortality.2, 9, 12 In some of the studies,
medication adherence predicted health outcomes;2, 9, 12 while in others it did not.30, 31 The
different results from previous studies may reflect the manner in which adherence was
operationalized. For example, in one study,9 investigators used clinician estimates to place
patients in a adherent or nonadherent group (i.e., 80% used as the cutpoint to form the two
groups) in a sample of 7599 patients with HF. Investigators found that good adherence was
associated with lower all-cause mortality. However, Billups, et al.30 studied the relationship
between drug therapy nonadherence and health outcomes in 1054 patients at high risk for drug-
related problems. Eighty percent was also chosen as the cutpoint. The investigators found that
adherence was not a predictor of concurrent or future hospitalization, mortality, or health care
costs. Without an evidence-based cutpoint, it is hard to judge which result is more trustworthy.
Eighty percent is the most commonly used cutpoint to dichotomize patients into adherent or
nonadherent groups,9-11, 32-40 although other investigators chose 75%12, 13 or 90%41, 42
as cutpoints. The rationale for choosing 75%, 80% or 90% was either not given or arbitrarily
chosen by prior investigators. Many investigators used pharmacy computer databases to
retrieve patients’ prescription refill history and calculate the refill rate to define medication
adherence rates. In such studies, patients who refilled 80%-120% of the mediations were
defined as adherent and those who refilled less than 80% or greater than 120% as nonadherent.
2, 43 Again, the cutpoint is not based on empirical evidence. The current study is the first to
generate empirical evidence on the level of adherence needed to achieve a longer time to event
in people with HF.
In addition to medication adherence, we demonstrated that beta-blocker use was an important
independent predictor of event-free survival. Along with medication adherence, beta-blocker
use predicted a longer time to the composite endpoint. Multiple large scale, multicenter,
randomized controlled trials have demonstrated the importance of beta-blocker therapy to HF
patients outcomes.44 Our data are consistent with these data and current consensus guidelines.
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A strength of our study was use of the MEMS to measure medication adherence. The MEMS
is objective, non-invasive and accurate for measuring medication adherence in research
settings.45 The MEMS is superior to clinician-estimate, self-report or pharmacy refill methods
of measuring medication adherence.2, 9, 12, 13 The clinician-estimate method is a poor
measure of assessing actual patient adherence as it is subjective and indirect.46 The self-report
method is subject to recall bias and social desirability and lacks consistency in the detection
of patients who are nonadherent.15 Pharmacy refill measures are dissociated from actual
medication consumption.47 Obtaining serum drug levels is an objective and direct measure of
adherence, but such biological assays are invasive, not feasible for most settings, not affordable,
and not available for all drugs used.48
To our knowledge, there has been only one study conducted, in HIV-infected patients, in which
an evidence-based method was used to identify the cutpoint for medication adherence.49 In
that study, the investigators used the MEMS to measure medication adherence and cluster
analysis to determine what level of adherence to use to differentiate adherent patients from
nonadherent. Patients categorized as adherent had a larger drop in viral load and rise in
CD4+ cell count, demonstrating the importance of defining medication adherence
systematically.
Conclusion
In this study, we identified an evidence-based cutpoint by which to define medication
adherence in patients with HF. Patients who take 88% of their prescribed medication doses
and on 88% of days take the correct dose experience a longer event-free survival than patients
who are less adherent. These findings can be used by researchers in future studies of adherence
and by clinicians in evaluating their patients’ adherence levels.
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Figure 1.
Medication Adherence and Time to First Event of Emergency Department Visits,
Rehospitalization, or Mortality
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Table 1
Sample Characteristics and Comparison of Patients’ Characteristics in Adherent and Nonadherent Groupsa (N = 135)
Characteristics Total Sample Nonadherent n = 60 Adherent n = 75 P Value*
Age, years 61 ± 11 61 ± 12 61 ± 11 .815
Female 41 (30.4) 20 (33.3) 21 (28.0) .574
Black race 14 (10.4) 8 (13.3) 6 (8.0) .398
Education, years 12.7 ± 3.3 12.3 ± 3.3 12.7 ± 3.2 .502
Marital status .096
 Single 13 (9.6) 9 (15.0) 4 (5.3)
 Married 84 (62.2) 31 (51.7) 53 (70.7)
 Divorced 16 (11.9) 9 (15.0) 7 (9.3)
 Widowed 22 (16.3) 11 (18.3) 11 (14.7)
Living alone 40 (29.6) 18 (30.0) 22 (29.3) 1.0
Financial status .915
 Comfortable 32 (24.1) 13 (22.4) 19 (25.3)
 Enough to make ends meet 71 (53.4) 32 (55.2) 39 (52.0)
 Not enough to make ends meet 30 (22.6) 13 (22.4) 17 (22.7)
LVEF, % 34.6 ± 14.2 35.3 ± 14.0 34.1 ± 14.5 .646
NYHA functional class .595
 I/II 51 (38.9) 20 (35.1) 31 (41.9)
 III 61 (46.6) 27 (47.4) 34 (45.9)
 IV 19 (14.5) 10 (17.5) 9 (12.2)
Charlson comorbidity index 3.3 ± 1.7 3.7 ± 1.7 3.1 ± 1.6 .038
ACEI .127
 Yes 97 (71.9) 39 (65.0) 58 (77.3)
BB .584
 Yes 120 (88.9) 52 (86.7) 68 (90.7)
*
P value for comparison of adherent and nonadherent groups
a
Patients were classified as adherent when 88% or above of days they took correct dose.
Patients were classified as nonadherent if less than 88% of days they took correct dose. Data are presented as means ± SD, or N (%); ACEI = angiotensin-
converting-enzyme inhibitor; BB = beta blocker; LVEF = Left Ventricular Ejection Fraction; NYHA = New York Heart Association
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Table 2
Impact of Medication Adherence on Event-free Survival
Variables Hazard Ratio Wald Significance
*Dose-count a Cox regression model
Adherent vs. nonadherent based on
cutpoint of 88%
2.208 4.289 .038
Age 1.001 .005 .946
Gender .888 .074 .785
LVEF .981 1.383 .240
NYHA 1.015 .003 .953
Comorbidity 1.070 .227 .634
Med_ACEI .912 .042 .838
Med_BB .349 4.210 .040
**Dose-day b Cox regression model
Adherent vs. nonadherent based on
cutpoint of 88%
3.165 8.8770 .003
Age 1.004 .055 .815
Gender 1.013 .001 .977
LVEF .976 2.299 .129
NYHA .965 .018 .892
Comorbidity 1.045 .088 .766
Med_ACEI .934 .023 .879
Med_BB .330 4.729 .030
*χ2 = 16.526, P = .035;
**χ2 = 21.473, P = .006
a
Dose-count: % of prescribed number of doses taken;
b
Dose-day: % of days the correct number of doses taken
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